Yu Zhang

Signal Transduction and Targeted Therapy · with Fu · 2022

A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Whom Yu Zhang trusts

Their strongest outbound trust, strongest first, inferred from their citations.

  1. R. Medzhitov (in Immunology)

Papers from Yu Zhang's perspective

Ordered by how strongly the researchers Yu Zhang trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index (Nature Biotechnology)
  2. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. (Cancer Research)
  3. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates (Nature Biotechnology)
  4. Paul Ehrlich's magic bullet concept: 100 years of progress (Nature Reviews. Cancer)
  5. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. (Clinical Cancer Research)
  6. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential
  7. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. (The Lancet Oncology)
  8. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. (Journal of Clinical Oncology)
  9. Tumor microenvironment as a therapeutic target in cancer (Pharmacology and Therapeutics)
  10. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. (The Lancet)

Their papers